In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cameron Health: Is This The Cure For An Ailing ICD Market?

Executive Summary

Ten years ago, the ICD market was booming, now it's not, despite studies that show the device is underutilized. The increasing complexity of CRM devices, and in particular ICDs, has brought a host of problems - including major product recalls that in turn have created caution on the part of patients - and has done little to grow the market beyond single digits in recent years. Cameron Health believes it has the answer for a truly disruptive ICD with a contrarian twist: a simpler device that addresses major problems such as lead failures, inappropriate shocks, and the burdens of complexity.

You may also be interested in...



Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business

Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.

Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business

Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.

NICE In Brief

The U.K.’s National Institute for Health and Care Excellence OK’s subcutaneous ICD implantation, but recommends outcomes data collection. Vertebroplasty and kyphoplasty win recommendation in technology appraisal guidance. More news from NICE.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel